Evidence map›Paper›PMID 22015921›Full record

ReviewNature reviews. Drug discovery2011

Perspectives and opportunities for nanomedicine in the management of atherosclerosis.

Mark E Lobatto, Valentin Fuster, Zahi A Fayad, Willem J M Mulder

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Drug discovery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 161 papers.

0numbers the graph read from it
0cells of the map it votes in
161citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

161 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Key parameters for designing robust 2D and 3D spheroid models forBioengineering & translational medicine · 2025
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

101 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

4 authors.

Mark E LobattoTranslational and Molecular Imaging Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, BOX 1234, New York 10029, USA.
Valentin Fuster
Zahi A Fayad
Willem J M Mulder

Funding

Theranostic HDL nanoparticles for inflammatory macrophages in atherosclerosisR01EB009638 · NIBIB · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FAYAD, ZAHI A. · 2009 to 2016
$4.6M
A Surface Activable Nanoemulsion platform for Breast Cancer Diagnosis and TherapyR01CA155432 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MULDER, WILLEM · 2011 to 2015
$1.7M
NCI NIH HHS R01 CA155432NHLBI NIH HHS HHSN268201000045CNIBIB NIH HHS R01 EB009638
6 · The paper itself

Abstract

The use of nanotechnology for medical purposes--nanomedicine--has grown exponentially over the past few decades. This is exemplified by the US Food and Drug Administration's approval of several nanotherapies for various conditions, as well as the funding of nanomedical programmes worldwide. Although originally the domain of anticancer therapy, recent advances have illustrated the considerable potential of nanomedicine in the diagnosis and treatment of atherosclerosis. This Review elaborates on nanoparticle-targeting concepts in atherosclerotic disease, provides an overview of the use of nanomedicine in atherosclerosis, and discusses potential future applications and clinical benefits.

Indexed as

AnimalsAtherosclerosisDisease ManagementDrug Delivery SystemsHumansNanomedicineNanoparticles

Identifiers

PMID22015921
PMCPMC3623275

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.